Current perspectives on the impact of Kratom use

References

• Singh D, Narayanan S, Vicknasingam B. Traditional and non-traditional uses of Mitragynine (Kratom): a survey of the literature. Brain Res Bull. 2016;126(Pt 1):41–46. doi:10.1016/j.brainresbull.2016.05.00427178014
   PubMed Web of Science ®Google Scholar
• Ulbricht C, Costa D, Dao J, et al. An evidence-based systematic review of kratom (Mitragyna speciosa) by the Natural Standard Research Collaboration. J Diet Suppl. 2013;10(2):152–170. doi:10.3109/19390211.2013.79354123725528
   PubMedGoogle Scholar
• Brown PN, Lund JA, Murch SJ. A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: implications for products sold as kratom. J Ethnopharmacol. 2017;202:302–325. doi:10.1016/j.jep.2017.03.02028330725
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Gassaway MM, Kapoor A, et al. Synthetic and receptor signaling explorations of the mitragyna alkaloids: mitragynine as an atypical molecular framework for opioid receptor modulators. J Am Chem Soc. 2016;138(21):6754–6764. doi:10.1021/jacs.6b0036027192616
   PubMed Web of Science ®Google Scholar
• Kruegel AC, Grundmann O. The medicinal chemistry and neuropharmacology of kratom: a preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology. 2017;15;134 (Pt A):108–120.
   Web of Science ®Google Scholar
• Varadi A, Marrone GF, Palmer TC, et al. Mitragynine/Corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2. J Med Chem. 2016;59(18):8381–8397. doi:10.1021/acs.jmedchem.6b0074827556704
   PubMed Web of Science ®Google Scholar
• Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine. Addict Biol. 2018. doi:10.1111/adb.12639
   Web of Science ®Google Scholar
• Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27(3):21–27.1041694
   PubMedGoogle Scholar
• Singh D, Narayanan S, Vicknasingam B, Corazza O, Santacroce R, Roman-Urrestarazu A. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol. 2017;32(3). doi:10.1002/hup.2582
   PubMed Web of Science ®Google Scholar
• Ya K, Tangamornsuksan W, Scholfield CN, Methaneethorn J, Lohitnavy M. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): a systematic review. Asian J Psychiatr. 2019;43:73–82. doi:10.1016/j.ajp.2019.05.01631100603
   PubMed Web of Science ®Google Scholar
• Cinosi E, Martinotti G, Simonato P, et al. Following “the roots” of Kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries. Biomed Res Int. 2015;2015:968786. doi:10.1155/2015/96878626640804
   PubMed Web of Science ®Google Scholar
• Henningfield JE, Fant RV, Wang DW. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology (Berl). 2018;235(2):573–589. doi:10.1007/s00213-017-4813-429273821
   PubMed Web of Science ®Google Scholar
• Grundmann O, Brown PN, Henningfield J, Swogger M, Walsh Z. The therapeutic potential of kratom. Addiction. 2018;113(10):1951–1953. doi:10.1111/add.1437129949213
   PubMed Web of Science ®Google Scholar
• Prozialeck WC. Update on the Pharmacology and Legal Status of Kratom. J Am Osteopath Assoc. 2016;116(12):802–809. doi:10.7556/jaoa.2016.15627893147
   PubMed Web of Science ®Google Scholar
• Grundmann O. Patterns of Kratom use and health impact in the US-Results from an online survey. Drug Alcohol Depend. 2017;176:63–70. doi:10.1016/j.drugalcdep.2017.03.00728521200
   PubMed Web of Science ®Google Scholar
• Ash S. American Kratom Association In: Grundmann O, editor. Gainesville: University of Florida; 2017.
   Google Scholar
• Jansen KL, Prast CJ. Ethnopharmacology of kratom and the Mitragyna alkaloids. J Ethnopharmacol. 1988;23(1):115–119.3419199
   PubMed Web of Science ®Google Scholar
• Hassan Z, Muzaimi M, Navaratnam V, et al. From Kratom to mitragynine and its derivatives: physiological and behavioural effects related to use, abuse, and addiction. Neurosci Biobehav Rev. 2013;37(2):138–151. doi:10.1016/j.neubiorev.2012.11.01223206666
   PubMed Web of Science ®Google Scholar
• Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010;21(4):283–288. doi:10.1016/j.drugpo.2009.12.00320092998
   PubMed Web of Science ®Google Scholar
• Ahmad K, Aziz Z. Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study. J Ethnopharmacol. 2012;141(1):446–450. doi:10.1016/j.jep.2012.03.00922440259
   PubMed Web of Science ®Google Scholar
• Singh D, Muller CP, Vicknasingam BK. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug Alcohol Depend. 2014;139:132–137. doi:10.1016/j.drugalcdep.2014.03.01724698080
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Vicknasingam BK, et al. Severity of pain and sleep problems during Kratom (Mitragyna speciosa Korth.) Cessation among regular Kratom Users. J Psychoactive Drugs. 2018;50(3):266–274. doi:10.1080/02791072.2018.144323429558272
   PubMed Web of Science ®Google Scholar
• Singh DPD, Narayanan SPD, Muller CPPD, et al. Long-term cognitive effects of Kratom (Mitragyna speciosa Korth.) use. J Psychoactive Drugs. 2019;51(1):19–27. doi:10.1080/02791072.2018.155534530556488
   PubMed Web of Science ®Google Scholar
• Singh D, Muller CP, Vicknasingam BK, Mansor SM. Social functioning of Kratom (Mitragyna speciosa) users in Malaysia. J Psychoactive Drugs. 2015;47(2):125–131. doi:10.1080/02791072.2015.101261025950592
   PubMed Web of Science ®Google Scholar
• Saingam D, Assanangkornchai S, Geater AF, Balthip Q. Pattern and consequences of krathom (Mitragyna speciosa Korth.) use among male villagers in southern Thailand: a qualitative study. Int J Drug Policy. 2013;24(4):351–358. doi:10.1016/j.drugpo.2012.09.00423083922
   PubMed Web of Science ®Google Scholar
• Singh D, Murugaiyah V, Hamid SBS, et al. Assessment of gonadotropins and testosterone hormone levels in regular Mitragyna speciosa (Korth.) users. J Ethnopharmacol. 2018;221:30–36. doi:10.1016/j.jep.2018.04.00529626673
   PubMed Web of Science ®Google Scholar
• Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of Kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792–799.23212430
   PubMedGoogle Scholar
• Drug Enforcement Administration. Drugs of Abuse. A DEA Resource Guide Washington, D.C: United States Department of Justice, Drug Enforcement Administration; 2017:94.
   Google Scholar
• Drug Enforcement Administration. KRATOM (Mitragynine speciosa korth) (Street Names: thang, Kakuam, Thom, Ketum, Biak) United States Department of Justice, Drug Enforcement Administration; 2013.
   Google Scholar
• Guide S A guide to Kratom legality: where is Kratom legal? [cited 410, 2018] Available from: https://speciosaguide.com/guide-kratom-legality-kratom-legal/. Accessed 416, 2019.
   Google Scholar
• Archives TN. Psychoactive Substances Act 2016; 2016 Available from: http://www.legislation.gov.uk/ukpga/2016/2/crossheading/psychoactive-substances/enacted. Accessed 416, 2019.
   Google Scholar
• Office UKGH. List of most commonly encountered drugs currently controlled under the misuse of drugs legislation; 2017 Available from: https://www.gov.uk/government/publications/controlled-drugs-list–2/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation. Accessed 44, 2019.
   Google Scholar
• Gottlieb S. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse In: Services UDoHaH, editor. FDA US HHS; 2018 Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-scientific-evidence-presence-opioid-compounds. Accessed June 18, 2019.
   Google Scholar
• speciosa.org. Kratom Legality Map. Available from: http://speciosa.org/home/kratom-legality-map/. Accessed 44, 2019.
   Google Scholar
• EMCDDA. Kratom (Mitragyna speciosa) drug profile; 2015 Available from: http://www.emcdda.europa.eu/publications/drug-profiles/kratom. Accessed 44, 2019.
   Google Scholar
• Stogner JM. Predictions instead of panics: the framework and utility of systematic forecasting of novel psychoactive drug trends. Am J Drug Alcohol Abuse. 2015;41(6):519–526. doi:10.3109/00952990.2014.99836725774440
   PubMed Web of Science ®Google Scholar
• Olsen EO, O’Donnell J, Mattson CL, Schier JG. N. W. Notes from the field: unintentional drug overdose deaths with Kratom Detected — 27 States, July 2016–december 2017. Mmwr. 2019;68:326–327. doi:10.15585/mmwr.mm6814a230973850
   PubMed Web of Science ®Google Scholar
• Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011–2017. Clin Toxicol. 2019;1–8. doi:10.1080/15563650.2019.1569236
   Web of Science ®Google Scholar
• Cumpston KL, Carter M, Wills BK. Clinical outcomes after Kratom exposures: a poison center case series. Am J Emerg Med. 2018;36(1):166–168. doi:10.1016/j.ajem.2017.07.05128751041
   PubMed Web of Science ®Google Scholar
• Gershman K, Timm K, Frank M, et al. Deaths in Colorado attributed to Kratom. N Engl J Med. 2019;380(1):97–98. doi:10.1056/NEJMc181105530601742
   PubMed Web of Science ®Google Scholar
• Aggarwal G, Robertson E, McKinlay J, Walter E. Death from Kratom toxicity and the possible role of intralipid. J Intensive Care Soc. 2018;19(1):61–63. doi:10.1177/175114371771265229456604
   PubMedGoogle Scholar
• Antony A, Lee TP. Herb-induced liver injury with cholestasis and renal injury secondary to short-term use of Kratom (Mitragyna speciosa). Am J Ther. Epub 2018 June 15.
   Web of Science ®Google Scholar
• Hughes RL. Fatal combination of mitragynine and quetiapine – a case report with discussion of a potential herb-drug interaction. Forensic Sci Med Pathol. 2019;15(1):110–113.30498933
   PubMed Web of Science ®Google Scholar
• Kapp FG, Maurer HH, Auwarter V, Winkelmann M, Hermanns-Clausen M. Intrahepatic cholestasis following abuse of powdered kratom (Mitragyna speciosa). J Med Toxicol. 2011;7(3):227–231. doi:10.1007/s13181-011-0155-521528385
   PubMedGoogle Scholar
• Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO. Kratom: a dangerous player in the opioid crisis. J Community Hosp Internal Med Perspect. 2018;8(3):107–110. doi:10.1080/20009666.2018.146869329915645
   PubMed Web of Science ®Google Scholar
• Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharmacognosy Res. 2013;5(4):241–246. doi:10.4103/0974-8490.11880624174816
   PubMedGoogle Scholar
• Zhu Y, Wang F, Li Q, et al. Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metab Dispos. 2014;42(2):245–249. doi:10.1124/dmd.113.05540024301608
   PubMed Web of Science ®Google Scholar
• Pantano F, Tittarelli R, Mannocchi G, et al. Hepatotoxicity Induced by “the 3Ks”: Kava, Kratom and Khat. Int J Mol Sci. 2016;17(4):580. doi:10.3390/ijms1704058027092496
   PubMed Web of Science ®Google Scholar
• Smith KE, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–348. doi:10.1016/j.drugalcdep.2017.08.03428950240
   PubMed Web of Science ®Google Scholar
• Vivek Jayadeva MD, Alana Bunnag MD, Rachel Meyen MD, Iru Fernando MD. Kratom (Mitragyna speciosa) use in a veteran with chronic pain. Am J Psychiatry Residents’ J. 2017;12(3):13–15. doi:10.1176/appi.ajp-rj.2017.120305
   Google Scholar
• Prozialeck WC, Avery BA, Boyer EW, et al. Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019;70:70–77. doi:10.1016/j.drugpo.2019.05.00331103778
   PubMed Web of Science ®Google Scholar